Skip to contentT
TuHURA Biosciences, Inc.
T
HURATuHURA Biosciences, Inc. Q1 2025 · 10-Q
Revenue$0.00$0.00— vs Q1 2024 Net Income-$6.66M-$6.66MN/M vs Q1 2024 EPS Diluted-$0.15-$0.15N/M vs Q1 2024 Operating Cash Flow-$4,738,422N/M Free Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TuHURA Biosciences, Inc. · CIK 1498382 · Engraved from SEC EDGAR
derived
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end